{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:10:31Z","timestamp":1777417831149,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.canlet.2011.04.016","type":"journal-article","created":{"date-parts":[[2011,5,21]],"date-time":"2011-05-21T08:45:23Z","timestamp":1305967523000},"page":"81-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+\/H+ exchanger"],"prefix":"10.1016","volume":"308","author":[{"given":"Weina","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yani","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huawen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tianxiang","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2011.04.016_b0005","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1038\/sj.leu.2402741","article-title":"Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy","volume":"16","author":"Hochhaus","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.04.016_b0010","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.canlet.2011.04.016_b0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1365-2141.2000.02216.x","article-title":"Chronic myelogenous leukaemia","volume":"111","author":"Lee","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2011.04.016_b0020","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1097\/01.cco.0000357476.43164.6b","article-title":"First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults","volume":"21","author":"Ottmann","year":"2009","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.canlet.2011.04.016_b0025","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/14622416.9.1.105","article-title":"ABC multidrug transporters: structure, function and role in chemoresistance","volume":"9","author":"Sharom","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.canlet.2011.04.016_b0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2011.04.016_b0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.bbrc.2008.10.005","article-title":"Down-regulation of P-glycoprotein expression by sustained intracellular acidification in K562\/Dox cells","volume":"377","author":"Lu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2011.04.016_b0040","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1056\/NEJMoa0804953","article-title":"Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders","volume":"359","author":"Zhao","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2011.04.016_b0045","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.04.016_b0050","first-page":"568","article-title":"Effect of intracellular acidification on P-glycoprotein in drug-resistant K562\/A02 cells","volume":"17","author":"Lu","year":"2009","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.canlet.2011.04.016_b0055","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.04.016_b0060","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2141.2005.05468.x","article-title":"Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells","volume":"129","author":"Withey","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2011.04.016_b0065","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1158\/1535-7163.MCT-07-0148","article-title":"Inhibition of the mitogen-activated protein kinase pathway results in the down-regulation of P-glycoprotein","volume":"6","author":"Katayama","year":"2007","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2011.04.016_b0070","doi-asserted-by":"crossref","first-page":"17581","DOI":"10.1074\/jbc.M702206200","article-title":"PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway","volume":"282","author":"Liu","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.04.016_b0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1158\/0008-5472.CAN-05-1779","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase","volume":"66","author":"Zhou","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.04.016_b0080","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/sj.onc.1203467","article-title":"The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6\/Abl) have altered substrate preferences and activate similar intracellular signalling pathways","volume":"19","author":"Voss","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.04.016_b0085","first-page":"188","article-title":"Pharmacologic mitogen-activated protein\/extracellular signal-regulated kinase kinase\/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr\/Abl-expressing human leukemia cells","volume":"62","author":"Yu","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2011.04.016_b0090","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.1182\/blood-2002-12-3647","article-title":"Map kinase signaling pathways and hematologic malignancies","volume":"101","author":"Platanias","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2011.04.016_b0095","doi-asserted-by":"crossref","first-page":"26715","DOI":"10.1074\/jbc.M303264200","article-title":"Cross-talk between JNK\/SAPK and ERK\/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors","volume":"278","author":"Shen","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2011.04.016_b0100","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0959-437X(01)00258-1","article-title":"The JNK signal transduction pathway","volume":"12","author":"Weston","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2011.04.016_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/mc.20348","article-title":"The functional contrariety of JNK","volume":"46","author":"Bode","year":"2007","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.canlet.2011.04.016_b0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nature03914","article-title":"Interaction of phosphorylated c-Jun with TCF4 regulates intestinal cancer development","volume":"437","author":"Nateri","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2011.04.016_b0115","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1101\/gad.390506","article-title":"c-Jun\/AP-1 controls liver regeneration by repressing p53\/p21 and p38 MAPK activity","volume":"20","author":"Stepniak","year":"2006","journal-title":"Genes Dev."},{"key":"10.1016\/j.canlet.2011.04.016_b0120","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.emboj.7601587","article-title":"Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation","volume":"26","author":"Perdiguero","year":"2007","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2011.04.016_b0125","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/sj.onc.1206154","article-title":"MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion","volume":"22","author":"Mehta","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.04.016_b0130","doi-asserted-by":"crossref","first-page":"8301","DOI":"10.1038\/sj.onc.1208026","article-title":"Stat3 upregulates MEK5 expression in human breast cancer cells","volume":"23","author":"Song","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2011.04.016_b0135","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/MCB.22.1.270-285.2002","article-title":"Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2","volume":"22","author":"Esparis-Ogando","year":"2002","journal-title":"Mol. Cell Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511002382?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383511002382?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:30:05Z","timestamp":1759591805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383511002382"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0304383511002382"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2011.04.016","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of Imatinib resistance in BCR-ABL-positive leukemia after inhibition of the Na+\/H+ exchanger","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2011.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}